Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

BMC Cancer · 2021 · PMC8170812 · PMID 34078304

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The high-PLR group showed a trend towards earlier progression (median PFS of 5.7 months vs. 11.4 months in the low-PLR group) and lower OS (17.7 months vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.